Matches in Wikidata for { <http://www.wikidata.org/entity/Q66044409> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q66044409 description "clinical trial" @default.
- Q66044409 description "ensayu clínicu" @default.
- Q66044409 description "klinisch onderzoek" @default.
- Q66044409 description "клінічне випробування" @default.
- Q66044409 name "Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma" @default.
- Q66044409 name "Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma" @default.
- Q66044409 type Item @default.
- Q66044409 label "Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma" @default.
- Q66044409 label "Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma" @default.
- Q66044409 prefLabel "Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma" @default.
- Q66044409 prefLabel "Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma" @default.
- Q66044409 P1050 Q66044409-209862AE-A870-4B9F-8EF3-9DECD49246BB @default.
- Q66044409 P1050 Q66044409-22CC4344-10E3-4837-807E-1931D00DB884 @default.
- Q66044409 P1132 Q66044409-2328EFCC-0ADD-41A1-82A9-56ABEFE774B3 @default.
- Q66044409 P1476 Q66044409-3C3219CA-35E6-4722-84FB-72E3909D3395 @default.
- Q66044409 P2899 Q66044409-4556A535-943A-41CC-B3BB-F2AFAF59449E @default.
- Q66044409 P3098 Q66044409-5A1ECCF8-15F6-4564-97EC-6FE43B8D4DEE @default.
- Q66044409 P31 Q66044409-320E59DC-528C-44DF-92A9-C6AFAEEDD272 @default.
- Q66044409 P4844 Q66044409-719C9D95-1F26-474C-9152-E6949620DADF @default.
- Q66044409 P4844 Q66044409-B6E693BC-1F4B-483A-AB05-79A5DB2C94FE @default.
- Q66044409 P580 Q66044409-7A934BA0-3236-49D5-9588-ADCA9F701F00 @default.
- Q66044409 P582 Q66044409-EF361547-1353-40F4-B4DA-183631DA93AD @default.
- Q66044409 P6099 Q66044409-9240CC7D-60FE-43AD-89C0-673CA0F5EEFA @default.
- Q66044409 P6153 Q66044409-A350CE00-8B1F-48A7-AE82-B9863CD3057D @default.
- Q66044409 P8363 Q66044409-258EA3CB-B5A5-49EF-A7EE-96D3AF60FB8F @default.
- Q66044409 P859 Q66044409-03A1EBC8-85E8-4D56-9301-B3FE83E0AAFE @default.
- Q66044409 P1050 Q159701 @default.
- Q66044409 P1050 Q17300307 @default.
- Q66044409 P1132 "+1" @default.
- Q66044409 P1476 "A 6-week, Double Masked, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Twice-daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to Travoprost 0.004% in Reducing Intraocular Pressure in Patients With Normal Tension Glaucoma" @default.
- Q66044409 P2899 "+18" @default.
- Q66044409 P3098 "NCT03150160" @default.
- Q66044409 P31 Q30612 @default.
- Q66044409 P4844 Q2193376 @default.
- Q66044409 P4844 Q411517 @default.
- Q66044409 P580 "2017-09-21T00:00:00Z" @default.
- Q66044409 P582 "2017-12-04T00:00:00Z" @default.
- Q66044409 P6099 Q42825046 @default.
- Q66044409 P6153 Q507154 @default.
- Q66044409 P8363 Q78089383 @default.
- Q66044409 P859 Q507154 @default.